Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2006-02-27
2010-08-31
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S351000, C530S402000, C930S144000
Reexamination Certificate
active
07785579
ABSTRACT:
Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 5264209 (1993-11-01), Mikayama et al.
patent: 5292802 (1994-03-01), Rhee et al.
patent: 5447722 (1995-09-01), Lang et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5747639 (1998-05-01), Seely
patent: 5773582 (1998-06-01), Shin et al.
patent: 0 372 752 (1990-06-01), None
patent: 0 401 384 (1990-12-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO 94/05332 (1994-03-01), None
patent: WO 96/34015 (1996-10-01), None
patent: WO 97/32607 (1997-09-01), None
Li et al. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency. Acta Pharmacol Sin. Jun. 2001;22(6):549-55.
Saifer et al. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 Dalton poly-ethylene glycol. Adv Exp Med Biol. 1994;366:377-87.
Abuchowski, A. et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Catalase”,J. Biol. Chem., 1977, 252(11), 3582-3586.
Bradford, M.M. et al., “A Rapid and Sensitive Method for the Quantitation of Microgram Auantities of Protein Utilizing the Principle of Protein-Dye Binding”,Anal. Biochem., 1976, 72, 248-254.
Carswell, E.A. et al., “An Endotoxin-induced Serum Factor that Causes Necrosis of Tumors”,J. Proc. Natl. Acad. Sci. USA, 1975, 72(9), 3666-3670.
Habeeb, A.F.S.A., “Determination of Free Amino Groups in Proteins by Trinitrobenzenesulfonic Acid”,Anal. Biochem., 1966, 14, 328-339.
Monfardini, C. et al., “A Branched Monomethoxypoly (Ethylene Glycol) for Protein Modification”,Bioconjugate Chem., 1995, 6, 62-69.
Naoi, M. et al., “Alteration of the Substrate Specificity ofAspergillus oryzae β-Galactosidase by Modification with Polyethylene Glycol”,J. Appl. Biochem., 1984, 6, 92-102.
Pennica, D. et al., “Human Tumor Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin”,Nature, 1981, 312, 724-729.
Pyatak, P.S. et al., “Preparation of a Polyethylene Glycol: Superoxide Dismutase Adduct, and an Examination of Its Blood Circulating Life and Anti-Inflammatory Activity”,Res. Comm. Chem. Pathol. Pharm., 1980, 29(1), 113-127.
Stocks, S.J., “A Flurometric Assay of the Degree of Modification of Protein Primary Amines with Polyethylene Glycol”,Anal Biochem., 1986, 154, 232-234.
Streekishma, K. et al., “High-Level Expression, Purification, and Characterization of Recombinant Human Tumor Necrosis Factor Synthesized in the Methylotrophic YeastPichia pastoris”, Biochem., 1989, 28, 4117-4125.
Tsutsumi, Y. et al., “Chemical Modification of Natural Human Tumor Necrosis Factor-α with Polyethylene Glycol Increases its Anti-Tumor Potency”,Jap. J. Cancer Res., 1994, 85, 9-12.
Tsutsumi, Y. et al., “Intravenous Administration of Polyethylene Glycol-Modified Tumor Necrosis Factor-α Completely Regresses Solid Tumor in Meth-A Murine Sarcoma Model”,Jap. J. Cancer Res., 1994, 85, 1185-1188.
Tsutsumi, Y. et al., “In vivo Anti-Tumor Efficacy of Polyehylene Glycol-Modified Tumor Necrosis Factor-α against Tumor Necrosis Factor-Resistant Tumors”,Jap. J. Cancer Res., 1997, 87, 1078-1085.
Zalipsky, S. et al., “Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides”,Polyehtylene Glycol Chemistry: Biotechnical and Biomedical Applications, Harris, J.M. (ed.), Plenum Press, New York, 1992, 21, 347-370.
Tsutsumi, Y. et al., “Molecular Design of Hybrid Tumor Necrosis Factor-α III: Polyethylene Gycol—Modified Tumor Necrosis Factor-αhas Markedly Enhanced Antitumor Potency due to Longer Plasma Half-Life and Higher Tumor Accumulation”,Journal of Pharmacalogy and Experimental Therapeutics, American Society for Pharmacalogy, 1996, 278(3), 1006-1011.
Tsutsumi, Y. et al., “Molecular Design of Hybrid Tumor Necrosis Factor-α II: The Molecular Size of Polyethylene Glycol-Modified Tumour Necrosis Factor-Alpha Affects its Anti-tumour Potency”,Br J. Cancer, 1996, 74(7), 1090-1095.
Mark, et al., “Site-Specific Mutagenesis to Modify the Human Tumor Necrosis Factor Gene”,Methods Enzymol, 1987, 154, 403-414.
Tsutsumi, et al., “Molecular Design of Hybrid Tumour Necrosis Factor Alpha with Polyethylene Glycol Increases its Anti-tumour Potency”,Br. J. Cancer, 1995, 71(5), 963-968.
Satake-Ishikawa, et al., “Chemical Modification of Recombinant Human Granulocyte Colony-Stimulating factor by Polyethylene Glycol Increases its Biological Activity in Vivo”,Cell Struct Funct., 1992, 17(3), 157-160.
Nakamura, et al., “A Novel Recombinant tumor Necrosis Factor-Alpha Mutant with increased Anti—tumor Activity and Lower Toxicity”,Int;. J. Cancer, 1991, 48(5), 744-748.
Polaris Group
Romeo David S
Woodcock & Washburn LLP
LandOfFree
Modified tumor necrosis factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified tumor necrosis factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified tumor necrosis factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150348